1. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL. (12th June 2019) Authors: Langerbeins, P.; Bahlo, J.; Rhein, C.; Gerwin, H.; Cramer, P.; Fürstenau, M.; Al‐Sawaf, O.; von Tresckow, J.; Fink, A.M.; Kreuzer, K.; Vehling‐Kaiser, U.; Tausch, E.; Müller, L.; Eckart, M.; Schlag, R.; Freier, W.; Gaska, T.; Balser, C.; Reiser, M.; Stauch, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS. (23rd June 2022) Authors: Cramer, P.; Fürstenau, M.; Giza, A.; Robrecht, S.; Tausch, E.; Schneider, C.; Wendtner, C.-M.; Hoechstetter, M.; Schetelig, J.; Böttcher, S.; Dreger, P.; Fink, A.-M.; Langerbeins, P.; Al-Sawaf, O.; Fischer, K.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 539 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P681: EUROFLOW STANDARDIZATION TECHNIQUE AND NORMALIZATION PROCEDURES IN LONGITUDINAL FLOW CYTOMETRIC EXPRESSION ANALYSIS OF CD20 IN CLL PATIENTS RECEIVING ANTI-CD20 DIRECTED THERAPY. (23rd June 2022) Authors: Walter, P. J.; Schilhabel, A.; Cramer, P.; von Tresckow, J.; Kohlscheen, S.; Fischer, K.; Eichhorst, B.; Böttcher, S.; Brüggemann, M.; Kneba, M.; Hallek, M.; Ritgen, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 577 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Inhibition of DNA replication and miscoding potential of minor groove alkylation: Structure–function insight from 3-deazaadenosines. (16th September 2016) Authors: Malvezzi, S.; Angelov, T.; Farnung, L.; Aloisi, C.; Cramer, P.; Sturla, S.J. Journal: Toxicology letters Issue: Volume 258(2016)Supplement Page Start: S126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Complete blood collection‐based systemic inflammation biomarkers for patients with hidradenitis suppurativa. (7th May 2022) Authors: Gambichler, T.; Hessam, S.; Cramer, P.; Abu Rached, N.; Bechara, F.G. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 9(2022) Page Start: 1593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Recent structural studies of RNA polymerases II and III. (25th October 2006) Authors: Cramer, P. Journal: Biochemical Society transactions Issue: Volume 34:Number 6(2006) Page Start: 1058 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). (June 2017) Authors: Cramer, P.; von Tresckow, J.; Bahlo, J.; Robrecht, S.; Al‐Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.M.; Fischer, K.; Seiler, T.; von Weikersthal, L.Fischer; Hebart, H.; Kreuzer, K.A.; Ritgen, M.; Kneba, M.; Wendtner, C.M.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. (June 2017) Authors: Al‐Sawaf, O.; Bahlo, J.; Fischer, K.; Herling, C.; Bergmann, M.; Fink, A.M.; von Tresckow, J.; Langerbeins, P.; Cramer, P.; Stilgenbauer, S.; Wendtner, C.M.; Eichhorst, B.; Hallek, M.; Goede, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS. (June 2017) Authors: Kipps, T.J.; Fraser, G.; Coutre, S.E.; Brown, J.R.; Barrientos, J.C.; Barr, P.M.; Byrd, J.C.; O'Brien, S.M.; Dilhuydy, M.; Hillmen, P.; Jaeger, U.; Moreno, C.; Cramer, P.; Stilgenbauer, S.; Chanan‐Khan, A.A.; Mahler, M.; Salman, M.; Cheng, M.; Londhe, A.; Ninomoto, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. (June 2017) Authors: Cramer, P.; Demirkan, F.; Fraser, G.; Pristupa, A.; Bartlett, N.; Dilhuydy, M.; Loscertales, J.; Avigdor, A.; Rule, S.; Samoilova, O.; Goy, A.; Ganguly, S.; Poggesi, I.; Lavezzi, S.M.; De Nicolao, G.; de Jong, J.; Neyens, M.; Salman, M.; Howes, A.; Mahler, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗